Surbhi Sarna, the founder of nVision Medical, suffered from extremely painful cysts at the age of 13 yet her doctors couldn’t tell whether these were benign or cancerous. In 2010, she made good on her personal vow to develop technologies that can make women more active participants in their reproductive health and thus nVision was born.
While nVision is still just beginning its journey with a $4.4 million Series A round, it has a promising future in the development of a range of medical devices designed for faster, easier and more accurate women’s health diagnostics and treatment. Its first two products will have to undergo the strict Food and Drug Administration’s (FDA) approval process but the prospects are bright.
nVision’s two products are devices used for the detection of fallopian tube blockage and for grabbing cells from the female reproductive organs. Both are designed to provide women and their obstetrician-gynecologists the opportunity to detect cancer as early as possible without the need for expensive, inconvenient, and painful diagnostic procedures.
No comments:
Post a Comment